Differential Analgesic and Adverse Effects of 0.125% Bupivacaine vs. Ropivacaine Coadministered Epidurally with Morphine.
10.4097/kjae.2001.41.1.47
- Author:
Hyeon Jeong YANG
1
;
Yoon Sung KIM
;
Min Gu KIM
;
Hyeon Ju KIL
;
Myong Hee KIM
Author Information
1. Department of Anesthesiology, College of Medicine, Pocheon Jungmun University, Songnam, Korea.
- Publication Type:Original Article ; Randomized Controlled Trial
- Keywords:
Analgesia: pain;
postoperative;
Anesthetic techniques: epidural;
Anesthetics, local: bupivacaine;
ropivacaine
- MeSH:
Bupivacaine*;
Cesarean Section;
Female;
Fentanyl;
Humans;
Incidence;
Infusion Pumps;
Injections, Epidural;
Lidocaine;
Morphine*;
Pregnancy;
Visual Analog Scale
- From:Korean Journal of Anesthesiology
2001;41(1):47-51
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: This study aimed to compare analgesic efficacy and occurance of motor block and other side effects of a 48 hr postoperative continuous epidural infusion of 0.125% bupivacaine or ropivacaine with morphine. METHODS: Forty patients undergoing a Cesarean section were allocated randomly into two groups. Both groups received an epidural injection of 2.0% lidocaine 18 20 ml and 0.5% bupivacaine 2 5 ml with fentanyl 50microgram 20 minutes before surgical incision and received 2 mg of epidural morphine by bolus 40 minutes after surgical incision. For post-operative pain control, a continuous epidural infusion was started using a two day infusor containing 6 mg of morphine in 100 ml of 0.125% bupivacaine (Group 1, n = 20) or 100 ml of 0.125% ropivacaine (Group 2, n = 20). Visual analog scale (VAS) for pain during rest and movement, sensory change and motor blockade were assessed for 48 hrs. after surgery. RESULTS: There were no significant differences in VAS for pain during rest and movement. The incidences of side effect were similar in both groups. CONCLUSIONS: Using 0.125% bupivacaine with morphine via the epidural route provided similar pain relief and side effects as 0.125% ropivacaine with morphine.